Bergqvist R, Ahlqvist VH, Lundberg M, et al. - This population-based cohort study demonstrated a modest negative association of statin treatment with coronavirus disease 2019 (COVID-19) mortality. This observation backs the continued employment of statin treatment for medical prophylaxis according to current recommendations also during the COVID-19 pandemic.

• Data were obtained from Swedish health registers, and a cohort of 963,876 residents of Stockholm, Sweden, was followed from 1 March 2020 until 11 November 2020.

• Matching of prescription dispensation data to healthcare data and the Swedish Cause of Death Registry was done, and multivariable cause-specific survival analysis was performed.

• After accounting for a series of preexisting health conditions and other factors, a moderately lower risk of COVID-19 mortality [hazard ratio, 0.88] was observed in relation to statin treatment.

• The relationship was confirmed by sensitivity analyses and did not differ substantially across risk groups.